Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > A/O Sept. 08th ONCY's cash runway is until late Q4, 2024

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Sep 13, 2023 4:34pm

133 Views

Post# 35634715

RE:RE:RE:RE:A/O Sept. 08th ONCY's cash runway is until late Q4, 2024

Just a quick note. I really did not like the seeking alpha article but they did mention the recent financing.

ONCY bolstered their cash funds at the end of July with a $15 million deal for shares and warrants, the latter at an exercise price of $2.81 for 60 months. Exercising their over-allotment option yielded another $2.25 million.

At this burn rate, with the extra money in the tank, this means that ONCY will be able to sustain operations for 5 to 6 more quarters.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec